نتایج جستجو برای: liposomal amphotericin b

تعداد نتایج: 904317  

2014
Adrián Imbernón José Luis Agud María Soledad Cuétara José Carlos Casqueiro Pilar Nuñez Alegría R. Domínguez Eusebio Bullido Alberto M. Stchigel

We present a case of rhino-orbitary mucormycosis which progressed despite liposomal amphotericin and early surgical debridement. Combined echinocandin and high dose liposomal amphotericin, repeated debridement, prolonged therapy with hyperbaric oxygen and continued therapy with posaconazole, along with strict diabetic control, allowed cure without disfigurement.

2013
Jyotsna Mishra Ayan Dey Niti Singh Ramesh Somvanshi Sarman Singh

BACKGROUND & OBJECTIVES Current therapy for leishmaniasis is limited and unsatisfactory. Amphotericin B, a second-line treatment is gradually replacing antimonials, the first-line treatment and is used as the preferred treatments in some regions. Though, presently it is the only drug with highest cure rate, its use is severely restricted by its acute toxicity. In the present study novel lipid-a...

Journal: :Journal of clinical microbiology 2003
Isabelle Durand-Joly Serge Alfandari Zinnédine Benchikh Marion Rodrigue Ana Espinel-Ingroff Benoit Catteau Christophe Cordevant Daniel Camus Eduardo Dei-Cas Francis Bauters Laurence Delhaes Stéphane De Botton

A disseminated Fusarium oxysporum infection with skin localization was diagnosed in a woman with a relapse of B-acute leukemia during induction chemotherapy. The infection was refractory to amphotericin B-lipid complex alone but responded successfully when voriconazole was added.

2007
Ga Won Jeon Soo Hyun Koo Jang Hoon Lee Jong Hee Hwang Sung Shin Kim Eun Kyung Lee Wook Chang Yun Sil Chang Won Soon Park

PURPOSE Amphotericin B is considered the treatment of choice for systemic candidiasis, but adverse effects may limit its use. An alternative option for the treatment of candidiasis includes lipid preparations of amphotericin B. This study investigated the safety and efficacy of AmBisome, a lipid formulation of amphotericin B containing liposomal structures, for the treatment of systemic candidi...

2017
Carolina Velez-Mejia Juan Velez-Londoño

Prototheca wickerhamii rarely causes systemic infection in humans but when it occurs, there are coexisting comorbidities. This case illustrated shows the manifestation of this opportunistic microorganism in an immunosuppressed patient. The patient was successfully treated with Liposomal amphotericin B with complete resolution of the lesions.

Journal: :Antimicrobial agents and chemotherapy 2002
Montserrat Ortoneda Javier Capilla Francisco J Pastor Isabel Pujol Josep Guarro

We have compared the activities of liposomal amphotericin B (LAMB) at 3, 5, 10, and 20 mg/kg/day and amphotericin B deoxycholate (AMB) at 1.5 and 2.5 mg/kg/day in a murine systemic infection by Fusarium verticillioides. Survival was improved by all treatments except AMB at 1.5 mg/kg/day. The tissue burden in liver was reduced by LAMB at all dosages and by AMB at 2.5 mg/kg/day. The two highest d...

Journal: :Antimicrobial agents and chemotherapy 2003
Ashraf S Ibrahim Valentina Avanessian Brad Spellberg John E Edwards

The efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB) were compared in a diabetic murine model of hematogenously disseminated Rhizopus oryzae infection. At 7.5 mg/kg of body weight twice a day (b.i.d.), LAmB significantly improved overall survival compared to the rates of survival in both untreated control mice (P = 0.001) and mice treated with 0.5 mg of AmB pe...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید